• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

    18.66 -0.57 (-2.96%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 29, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Summit Therapeutics Inc. - Common Stock

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    16 17 Next >
    Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
    The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a late-stage clinical study. 
    Via The Motley Fool
    This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
    There's a lot of hope for ivonescimab, but are investors being a bit too bullish? 
    Via The Motley Fool
    How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
    BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days. 
    Via Investor's Business Daily
    Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
    Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... 
    Via Benzinga
    Here's Why Everyone's Talking About Summit Therapeutics
    Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. 
    Via The Motley Fool
    Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today
     
    Via Benzinga
    Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment
     
    Via Benzinga
    Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
     
    Via Benzinga
    Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
    From Summit Therapeutics Inc.
    Via Business Wire
    Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
    These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings. 
    Via Benzinga
    Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
    A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy. 
    Via The Motley Fool
    Why Summit Therapeutics Skyrocketed 123% This Week
    Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers. 
    Via The Motley Fool
    Why Summit Therapeutics Stock Is Soaring Again Today
    This high-flying biotech stock is moving even higher -- and for good reason. 
    Via The Motley Fool
    Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday
     
    Via Benzinga
    Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
    The company is adding onto its success outperforming Merck's top drug in lung cancer patients. 
    Via Investor's Business Daily
    Summit Therapeutics Surges on Trial Results: Time to Buy?
    Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab. 
    Via MarketBeat
    Why Summit Therapeutics (SMMT) Stock Is Rising Today
    Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net proceeds. 
    Via Benzinga
    Summit Therapeutics Raises $235 Million
    From Summit Therapeutics Inc.
    Via Business Wire
    Is Summit Therapeutics a Buy Now?
    The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug. 
    Via The Motley Fool
    Why Summit Therapeutics Rocketed Over 60% Today
    The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market. 
    Via The Motley Fool
    Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
     
    Via Benzinga
    Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday
     
    Via Benzinga
    Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
    Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The biotech stock rallied 30%. 
    Via Investor's Business Daily
    Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
    Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free survival compared to Merck's Keytruda in non-small cell lung cancer patients,... 
    Via Benzinga
    Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
    From Summit Therapeutics Inc.
    Via Business Wire
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire
    HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
    From Summit Therapeutics Inc.
    Via Business Wire
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire
    SMMT Stock Earnings: Summit Therapeutics Beats EPS for Q2 2024
    SMMT stock results show that Summit Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    16 17 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.